Figures (4)  Tables (3)

    • Figure 1. 

      Mean change of sNfL from baseline (pg/mL).

    • Figure 2. 

      Mean change in CIPN6 scores from baseline.

    • Figure 3. 

      Mean change in TNSn© scores from baseline.

    • Figure 4. 

      sNfL individual values by timepoint.

    • Variable N (%) or Mean (SD)
      Age Mean (SD) 54.8 (11.6)
      Median (range) 54.5 (38.0–79.0)
      Sex Male 19 (67.9%)
      Female 9 (32.1%)
      Race Caucasian 22 (78.6%)
      African American 5 (17.9%)
      Other 1 (3.6%)
      Cumulative chemotherapy dose (mg) Mean (SD) 624.0 (181.7)
      Median (range) 648.5 (259.9–1,019.6)

      Table 1. 

      Baseline characteristics (N = 28).

    • Variable Mean SD Median Minimum Maximum
      sNfL (pg/mL)
      Baseline (n = 28) 23.8 14.1 19.6 1.7 49.4
      Mid-treatment (n = 24) 27.6 16.0 21.0 8.6 72.3
      End of treatment (n = 23) 46.7 39.8 44.6 2.0 160.0
      3 months post (n = 20) 61.1 47.6 51.1 2.0 160.0
      CIPN6
      Baseline (n = 28) 6.6 1.5 6.0 6.0 12.0
      Mid-treatment (n = 21) 9.5 4.0 9.0 6.0 20.0
      End of treatment (n = 25) 11.7 5.0 10.0 6.0 23.0
      3 months post (n = 19) 12.4 5.6 13.0 6.0 24.0
      TNSn©
      Baseline (n = 28) 0.5 0.9 0.0 0.0 4.0
      Mid-treatment (n = 23) 1.0 1.3 0.0 0.0 4.0
      End of treatment (n = 24) 2.6 2.7 2.0 0.0 9.0
      3 months post (n = 18) 2.9 3.1 2.5 0.0 10.0

      Table 2. 

      Descriptive statistics of outcomes by time.

    • Outcomes Mean ± SD Adjusted change from
      baseline* Mean [95% CI]      		 p-value**
      sNfL(pg/mL)
      Baseline (n = 28) 23.8 ± 14.0
      Mid-treatment (n = 24) 27.6 ± 16.0 3.4 [−11.5, 18.4] 0.6501
      End of treatment (n = 23) 46.7 ± 39.8 21.8 [6.6, 37.0] 0.0168
      3 months post (n = 20) 61.1 ± 47.6 36.9 [21.1, 52.8] < 0.0001
      CIPN6
      Baseline (n = 28) 6.6 ± 1.5
      Mid-treatment (n = 21) 9.5 ± 4.0 2.6 [0.5, 4.6] 0.0525
      End of treatment (n = 25) 11.7 ± 5.0 5.1 [3.2, 7.1] < 0.0001
      3 months post (n = 19) 12.4 ± 5.6 6.4 [4.2, 8.6] 0.0001
      TNSn©
      Baseline (n = 28) 0.5 ± 0.9
      Mid-treatment (n = 23) 1.0 ± 1.3 0.5 [−0.5, 1.5] 0.8610
      End of treatment (n = 24) 2.6 ± 2.7 2.2 [1.2, 3.2] < 0.0001
      3 months post (n = 18) 2.9 ± 3.1 2.6 [1.5, 3.7] < 0.0001
      * Adjusted for age, sex, race, and cumulative chemotherapy dose with LMM.
      ** Bonferroni corrected.

      Table 3. 

      Change from baseline.